Coya Therapeutics (COYA) EBT (2022 - 2026)

Coya Therapeutics has disclosed EBT across 5 years of filings, most recently posting -$6.6 million for Q2 2026.

• In Q2 2026, EBT fell 8.91% year-over-year to -$6.6 million; the TTM figure through Jun 2026 stood at -$22.3 million (down 1.72% YoY), while the FY2025 annual figure was -$21.2 million, down 36.04% from the prior year.
• EBT came in at -$6.6 million for Q2 2026 at Coya Therapeutics, up from -$7.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.8 million in Q4 2023 to a low of -$7.3 million in Q1 2025.
• Average EBT over 5 years is -$3.9 million, with a median of -$3.5 million recorded in 2022.
• Year-over-year, EBT soared 190.6% in 2023 and plunged 324.79% in 2024.
• Over 5 years, EBT stood at -$2.0 million in 2022, then soared by 190.6% to $1.8 million in 2023, then tumbled by 324.79% to -$4.1 million in 2024, then sank by 47.81% to -$6.0 million in 2025, then fell by 10.07% to -$6.6 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$6.6 million in Q2 2026, -$7.2 million in Q1 2026, and -$6.0 million in Q4 2025.